The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).
 
Aiwu Ruth He
Consulting or Advisory Role - Eisai; Genentech/Roche; Merck
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Exelixis
Research Funding - Genentech; Merck
 
Alexander Y. Kim
Honoraria - Sirtex Medical
Consulting or Advisory Role - Genentech/Roche; Sirtex Medical; TriSalus Life Sciences
Research Funding - Sirtex Medical; TriSalus Life Sciences
Travel, Accommodations, Expenses - Genentech/Roche; Sirtex Medical; TriSalus Life Sciences
 
Beau M Toskich
No Relationships to Disclose
 
Kabir Mody
Stock and Other Ownership Interests - CytoDyn; Oncotherapeutics
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Genentech/Roche; Ipsen; Merrimack; Vicus Therapeutics
Research Funding - Agios; ARIAD; ArQule; AstraZeneca (Inst); Basilea (Inst); FibroGen; Gritstone Bio (Inst); Incyte (Inst); MedImmune; Merck (Inst); Senhwa Biosciences; Taiho Pharmaceutical; TRACON Pharma; Turnstone Bio (Inst); Vyriad (Inst)
 
Kevin Kim
Consulting or Advisory Role - Boston Scientific; Eisai; Genentech/Roche; Sirtex Medical
Research Funding - Galil Medical; Galil Medical; Galil Medical
 
Stacey Stein
Consulting or Advisory Role - Eisai; Genentech; Merck
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Taiho Pharmaceutical
 
Thomas Adam Abrams
Stock and Other Ownership Interests - Guardant Health; InVitae; Jounce Therapeutics
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Exelixis/Ipsen; Merck
Research Funding - Lilly
Expert Testimony - Genentech
 
Daniel Brown
Consulting or Advisory Role - Bard Medical; Sirtex Medical
Research Funding - Sirtex Medical
 
Laura Williams Goff
Consulting or Advisory Role - Bayer/Onyx; Competitive Drug Development International; Eisai; Lilly; Newlink Genetics; QED Therapeutics
Research Funding - Agios; ArQule; ASLAN Pharmaceuticals; Astellas Pharma; Basilea; BeiGene; Bristol-Myers Squibb; H3 Biomedicine; Incyte; Leap Therapeutics; Lilly; Merck (Inst); Merck (Inst); Onyx; Pfizer; Sun Pharma
 
Richard D. Kim
Honoraria - Bristol-Myers Squibb; Lilly
Consulting or Advisory Role - Array BioPharma; Bayer; Bristol-Myers Squibb; Lilly
Speakers' Bureau - Lilly
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst)
 
Nainesh Parikh
No Relationships to Disclose
 
Tyler Sandow
No Relationships to Disclose
 
Daniel Johnson
No Relationships to Disclose
 
Renuka V. Iyer
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Exelixis; Ipsen; Lexicon; Merck; Novartis; QED therapeutics; Sun pharma
Research Funding - Cleveland BioLabs (Inst); Genentech/Roche (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Michael Petroziello
No Relationships to Disclose
 
Smitha S. Krishnamurthi
Consulting or Advisory Role - Array BioPharma
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst)
 
Charles Martin
No Relationships to Disclose
 
Yixing Jiang
No Relationships to Disclose
 
Nabeel Akhter
No Relationships to Disclose